- Data for masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) highlight best-in-class therapeutic index and demonstrate clinical benefits in metastatic microsatellite-stable (MSS) colorectal cancer...
Adagene Appoints Heinz-Josef Lenz FACP to Strategic Advisory Board
SAN DIEGO and SUZHOU, China, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (œAdagene) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today...
- Interim data from additional MSS CRC patients dosed at 10 mg/kg every three weeks (Q3W) in combination with pembrolizumab anticipated in 2024 at a medical conference - - Initiated evaluation...
Adagene Presents Results Reinforcing Best-in-Class Profile of ADG126
- Interim results in MSS CRC suggest that SAFEbody precision masking technology enables a new standard for anti-CTLA-4 therapy at higher, more frequent and repeat doses by overcoming longtime...
- MSS CRC case examples reinforce optimal dosing regimen in ongoing phase 2 dose expansion, with a confirmed partial response at ADG126 10 mg/kg every three weeks plus pembrolizumab - Integrated...
- Data reinforces mechanism of action and selection of 10 mg/kg every three weeks repeat dosing regimen with pembrolizumab in ongoing MSS CRC dose expansion cohort “ SAN DIEGO and SUZHOU, China, Oct....
“ Adagene™s CEO, Dr. Peter Luo, participating in SITC webinar on September 22 focused on essential role of Treg depletion for anti-CTLA-4 therapies “ SAN DIEGO and SUZHOU, China, Sept. 07, 2023 ...
ADC Therapeutics is backing out of a 2019 collaboration with Adagene centered on developing ADCs using the latter biotech's antibody-building tech.